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Hepatitis C virus (HCV) is one of the viruses known to cause hepatic cancer. HCV is also believed to be involved in malignant
lymphoma. In this paper, we investigated characteristics of malignant lymphoma cases that were anti-HCV antibody (HCV-Ab)
positive. We were able to perform pathological examinations on 13 out of 14 HCV-positive cases. Of these, lymphoid tissues of 10
stained positive for HCV-Ab. There was no signiﬁcant correlation between the degree of HCV staining and the rate of recurrence
or resistance to treatment. However, there did appear to be a consistent decrease in the amount of HCV-RNA between pre- and
posttreatment among HCV-Ab-positive cases; that is, treatment-resistant cases that exhibited resistance from the ﬁrst treatment
and recurrent cases more frequently had a higher HCV level at treatment termination compared to the pretreatment level. This
suggests that the HCV virus either accelerates oncogenesis by direct interaction with B cells or indirectly aﬀects lymphoma
prognosis.
1.Introduction
Since the discovery of hepatitis C virus (HCV) in 1989, the
causal relationship between HCV and hepatic cancer has
been proven through various case control studies, and it has
been suggested that the risk of hepatic cancer in the HCV-
infectedpopulation is23–35-times higherthaninuninfected
healthy individuals [1, 2]. In some cases, however, HCV can
cause hepatic carcinoma without leading to the development
of hepatic cirrhosis. The mechanism by which HCV causes
cancer is therefore not clear [2]. Several reports indicate
a correlation between malignant lymphoma and HCV
infection [3, 4] whereas other reports showed no correlation
[1]. A deﬁnitive answer on the relationship between HCV
infection and malignant lymphoma is therefore lacking. We
previously reported recurrence of malignant lymphoma in
clinical cases which had altered anti-HCV antibody (HCV-
Ab) levels or in those with abnormally high HCV-RNA level
during chemotherapy treatment for lymphoma [5, 6]. In this
study, we analyzed the incidence of malignant lymphoma
among HCV-Ab-positive cases and characteristics and
prognoses observed in our hospital, and we compared the
results with previously reported cases.
2. Patients andMethods
2.1. Patients. Analysis of HCV-Ab-positive patients was
conducted between October 2002 and December 2010,
during the period that rituximab was marketed and available
in Japan. One hundred eighty cases of B lymphocyte non-
Hodgkin’s lymphoma (NHL) were used as a control group
and were treated around the same period of time. The HCV-
Ab positive group consisted of 14 patients between 43 and 90
years old with a median age of 72 years. These cases included
12 with diﬀuse large B cell lymphoma, 1 with mantle cell
lymphoma, and 1 with EB virus-related lymphoproliferative
disorder. Eight cases were of grades III and IV, and no gender
diﬀerences were observed. Eight cases (57%) were either
treatment resistant at the time of ﬁrst treatment or were
recurrent cases. The median age of the control group was 662 Advances in Hematology
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Abbreviations: HCV as hepatitis C virus; DLB as diﬀuse large B cell
lymphoma; FL as follicular lymphoma; MALT as maltoma; MCL as mantle
cell lymphoma; Burkitt lymphoma; LPD as Iymphoproliferative disease; L
as low risk; LI as low-intermediate risk; IH as intermediate-high risk: H as
high risk of international prognostic index.
years and the male/female ratio was approximately the same.
However, the incidence of diﬀuse large B cell lymphoma in
this group was 60% and was seen to be less than the anti-
HCV-Abpositivegroup.Therewereseventy-onecases(31%)
with ﬁrst treatment resistance or recurrence in the control
group, and the ratio was less than that seen in the anti-HCV-
Ab positive group (Table 1).
2.2. HCV Immunohistochemical Staining of Lymphoid Tissues.
Specimens consisted of lymph nodes (7 cases), stomach
(2), tonsil (1), rectum (1), soft tissue (1), and orbit (1).
Specimens were ﬁxed in 10% neutral-buﬀered formalin,
embedded in paraﬃn. Diagnosis for malignant lymphoma
was made by HE and immunohistochemical staining.
To evaluate HCV positivity of lymphoma cells, immuno-
histochemical staining was performed using monoclonal
antibodies to hepatitis C virus (NS3) NCL-HCV-NS3 (Leica
Microsystems, Weltzlar, Germany). HCV-speciﬁc reactions
were detected with commercially available Histoﬁne simple
stain (Nichirei Co., Tokyo, Japan). Immunoreactivity was
graded as negative, weakly positive, and strongly positive
(Figures 1(a), 1(b),a n d1(c)).
2.3. Survival. Survival and progression-free survival (PFS)
probabilities were estimated with the Kaplan-Meier Method.
Overall survival (OS) was calculated from the date of
diagnosis to the date of a patient’s death for any reason
or to last followup. PFS and relapse were determined with
cumulative incidence estimates, treating relapse and death
as competing risk events. All time-to-event endpoints were
censored at the time of last contact.
3. Results
3.1. Pathological Examination by Immunohistochemical Stain-
ing with Anti-HCV Antibody. Immunohistopathological
analysis of anti-HCV-Ab positive lymphoma cells revealed
5 strongly positive, 5 weakly positive, and 3 negative cases.
These observations indicate that the growth and develop-
ment of lymphoma cells may be associated with the presence
of HCV. The level of HCV staining was also analyzed to
determine if a correlation to treatment resistance or recur-
rence potential existed. Although the number of cases was
too limited to obtain a clear conclusion, 3 out of 5 strongly
positivecaseswerealsotreatmentresistantorrecurrentcases.
Among 5 weakly positive cases, 3 were treatment resistant or
recurrent cases. There were only 3 negative cases, 2 of which
were treatment-resistant or recurrent cases. It would there-
fore be diﬃcult to predict treatment-resistance or recurrence
based on immunoreactivity. These results indicate that HCV
directly interacts with B lymphocytes and causes lymphoma,
however, the outcome cannot be predicted.
3.2. Characteristics of Anti-HCV-Ab Positive Cases. One pa-
tient with grade I disease who had undergone surgery was
excluded from the study and the remaining 13 cases were
analyzed. Among these, 11 had liver disorder and 2 exceeded
Grade III. Increased bilirubin was also seen in 2 cases. HCV-
RNA level increased in 10 cases during the treatment period
but only 9 of them appeared to cause hepatic toxicity. In 5
cases, HCV-RNA transiently decreased after hepatic toxicity
but never become undetectable. The level of HCV-RNA
prior to or just before treatment was compared with that
on the last day of visit (including the treatment period).
A decrease in HCV-RNA was considered to have occurred
when the ratio of HCV-RNA on the last visit/pre-treatment
HCV-RNA was less than 1.0. Figure 2 shows the changes
in HCV-RNA from these cases. HCV was measured pre-,
postthird, and postsixth treatments. Many cases showed an
increase in HCV-RNA after the third treatment. In cases
with treatment resistance or recurrence, HCV-RNA afterthe
sixth treatment was never lower than the pre-treatment
level. In contrast, although HCV-RNA increased after the
third treatment in many cases which maintained complete
remission, most cases among these showed a decrease in
HCV-RNA after the sixth treatment. In cases with constantly
low levels of HCV-RNA, lymphoma tissues showed positive
staining for anti-HCV antibody, however, HCV-RNA was
not detectable throughout the treatment course. In one case
that maintained complete remission, interferon treatment
was added following anticancer treatment and HCV-RNA
became nondetectable. The analysis showed that there was
no treatment resistance or recurrence among cases with
decreased HCV-RNA whereas treatment resistance or recur-
rence did occur in cases with increased HCV-RNA (Table 2).
3.3. Overall Survival and Progression Free Survival. Figure 3
shows progression free survival and overall survival in our
institute calculated by the Kaplan-Meier method. There
seemed to be no signiﬁcant diﬀerence in progression free
survival between the anti-HCV-Ab-positive group and theAdvances in Hematology 3
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Figure 2: (a) The change in HCV-RNA in cases with treatment resistance or recurrence. (b) The change in HCV-RNA in cases that
maintained remission. In many cases that showed treatment resistance or recurrence, HCV-RNA levels transiently increased after the third
anti-cancer treatment compared to pretreatment levels. Although in two cases HCV-RNA level decreased compared to pre-treatment level,
values were higher than the pre-treatment level after the sixth treatment. In contrast, in some of the cases that maintained remission, HCV-
RNA levels increased transiently after the third treatment, but after the sixth treatment decreased to lower than pre-treatment levels.
Table 2: Tendency of the anti-HCV-antibody-positive patients.
Complication of hepatitis 11
AST/ALT
Grade I/II 9
above Grade III 2
T-Bil
Grade I/II 1
above Grade III 1
HCV RNA elevation during chemotherapy 10
HCV RNA elevation with hepatitis 9
Reduction of transient HCV RNA after hepatic toxicity 5
Recurrence or refractory
Last time/ﬁrst time HCV RNA below 1.0 0/5
Last time/ﬁrst time HCV RNA above 1.0 8/8
Abberiviatins: HCV as hepatitis C virus; T-Bil as total bilirubin; AST as
aspartate aminotransferase; ALT as alanine transaminase.
control group, however, overall survival appears to be higher
in anti-HCV-Ab-negative group. Due to the small sample
size of anti-HCV-Ab-positive cases, however, the diﬀerence
did not reach statistical signiﬁcance.
4. Discussion
Various reports have suggested an association between
HCV and malignant tumors, particularly hepatic cancer. A
correlation between HCV and B cell lymphoma was also
reported recently [7–12]. We also observed recurrent cases
of B cell lymphoma which were associated with a rapid
increase in HCV viral load, indicating a role for HCV in B
cell lymphoma progression [5] .I nt h i ss t u d y ,w ei n v e s t i g a t e d
the correlation between anti-HCV-Ab positivity and B cell
lymphoma by performing immunohistochemical staining
on pathological samples. Almost all cases showing weak or
strongly positive staining were also HCV positive. Although
lymphoid cells may simply be positive for HCV antigen, this
result also may indicate a possible correlation between HCV
and lymphoma. Although the majority of cases in this study
were diﬀuse large B cell lymphoma, an association between
HCV and marginal zone lymphoma, small lymphocytic
lymphoma/chronic lymphocytic lymphoma, lymphoplas-
macytic lymphoma and follicular center lymphoma has
also been reported [13–15]. Several studies also indicate
a correlation between HCV and B cells. For example, it
has been reported that HCV-RNA can be maintained over
a prolonged period in B cells and that activation-induced
cytidine deaminase increases in these cells, which may aﬀect4 Advances in Hematology
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Figure 3: Progression free survival (a) and overall survival (b) curves of non-Hodgkin’s lymphoma patients who were anti-HCV-antibody
negative (B) and anti-HCV antibody positive (A). Both survival parameters were lower in anti-HCV antibody positive patients, however, no
signiﬁcant diﬀerence was seen when comparing these two groups.
lymphocyte growth [13, 16]. It is possible that the growth
of B cells that utilize these particular signals may contribute
to the progression of B cell lymphoma at the level of
DNA replication, however, further studies are needed to
clarify this relationship. There was, however, no correlation
between the level of HCV staining and prognosis. Although
it is possible that HCV is directly involved in lymphoma
development, there seems to be no correlation between HCV
infection of lymphoma cells and prognosis, and only indirect
involvement of HCV is therefore suggested.
It was not possible to perform statistical analyses in this
studyduetothesmallnumberofantiHCV-Abpositivecases.
Nevertheless, the overall survival data suggested a poorer
prognosis in the anti HCV-Ab positive group compared
to the HCV-Ab negative B cell lymphoma group. Previous
reports have been inconsistent, however. One study reported
no change in prognosis, including recurrence rate. Other
studies reported a reduction in progression free survival,
but no eﬀect on overall survival. In additional studies,
a reduction in both progression free survival and overall
survivalwasreported[17–19].Inordertoclarifytheseincon-
sistent observations, it is desirable to conduct experiments
on patient groups with deﬁned disease and analyzed under
identical conditions.
We also compared the characteristics of B cell lymphoma
patients to anti-HCV-Ab positivity with regard to the level
of HCV-RNA. An increase in HCV-RNA was observed in
10 anti-HCV-Ab positive cases. Among these, 8 cases had
a higher level of HCV-RNA at the completion of treatment
compared to the level at initial visit (pre-treatment HCV-
RNA level). As reported by Ennishi et al., although HCV
viral load increased upon treatment of the lymphoma, in a
majority of cases, the amount of virus decreased over 1–6
months following treatment. This indicates that, although
few in number, cases occurred in which the amount of virus
did not decrease to the pre-treatment level [17]. We also
observed no reduction in HCV-RNA in some recurrent or
treatment-resistant cases, when compared to the level at
initial visit. There was also no recurrence seen in those in
whom the level of HCV-RNA had declined at the completion
of treatment compared to the ﬁrst visit. This indicates that
unless HCV-RNA returns to the pre-treatment level at the
e n do ft r e a t m e n t ,r e p e a t e dr e c u r r e n c ec a no c c u ri ns o m e
cases, indicating that it may be possible to predict prognosis
based on the viral load at the end of treatment. In fact, it has
been reported that ribavirin was eﬀective in HCV-positive
cases [16, 20, 21] and that there was a reduction in the
development of lymphoma when interferon was eﬀectively
used for treatment [22]. Interferon has been shown to
be eﬀective for suppression of HCV and prevention of
hepatic carcinoma, and it may also therefore be eﬀective
for malignant lymphoma. Decisions on treatment options
should therefore include, for example, concurrent use of
interferon from initial treatment and during maintenance
therapy, as such treatments have the potential to prevent
hepatic carcinoma as well. Although there are problems with
such therapies, including a myelosuppressive eﬀect due to
concomitant drug use and high cost, the potential beneﬁts
warrant conduction of a large-scale clinical study.
Hepatic toxicity due to hepatitis B virus reactivation
during rituximab treatment has been well recognized [23],
and the possibility of similar severe hepatic toxicity resulting
from treatment with rituximab in HCV-positive cases has
also been discussed, although this is an unlikely event with
normalchemotherapy[17].Wehavealsoreportedpreviously
that anti-HCV-Ab declines while HCV-RNA increases dur-
ing rituximab treatment, and that the level of HCV-RNA
decreases when the interval of rituximab is extended [6].
We are therefore interested in large-scale studies conducted
by other groups. In a large-scale clinical study, Ennishi
et al., reported that hepatic toxicity was often found in
HCV positive cases, which led to modiﬁcation in treatment
schedule [17]. Pitini et al., analyzed a small number of
hepatitiscasesarising fromHCVreactivation. Althoughonly
4 cases were analyzed in this study, HCV genotype II tended
to be associated with hepatitis [24]. In our study, 11 out of 14
cases developed hepatitis, with one dying of hepatic failure.
In this particular case, hepatic failure rapidly progressed
during treatment. Since this patient also developed EBV
infection, the patient may have had an immune-deﬁcient
background. Two cases of Grade III and higher hepatic
toxicity were also observed. The frequency was not low, itAdvances in Hematology 5
is possible that hepatic toxicity was caused by an increased
HCV level, as seen with HBV infection, and by removal of
immune suppression. A decrease in HCV-RNA level after
hepatic toxicity was observed in 5 cases in the present study
and in 3 of these, the amount of HCV-RNA decreased to
below pre-treatment levels. In these cases, no recurrence was
observed. It may be possible to lower the recurrence rate by
reducing HCV-RNA level if there is no delay in treatment.
On the other hand, if hepatic toxicity occurs, the treatment
interval may have to be extended and as a result, treatment
eﬃcacy may be reduced. Therefore, hepatic toxicity should
be avoided after all. The use of rituximab may be eﬀective if
the risk level can be predicted via genotypic analysis of HCV
and identiﬁcation of other risk factors for hepatic toxicity.
Although we were unable to analyze these parameters in the
present study, a further largescale investigation is desirable.
In conclusion, although a ﬁrm relationship between
HCV and B cell lymphoma remains to be proven, there
appears to be a deﬁnite correlation between the two. Since
survival of anti-HCV-Ab positive lymphoma patients is not
necessarily higher than overall survival in anti-HCV-Ab
negative cases (it can in fact be lower), it may be possible to
improve survival through the use of interferon treatment.
The frequency is not low, and the use of rituximab may
cause further severe hepatic toxicity. Recurrence and
other problems may decrease if HCV-RNA level consistently
declinesandchemotherapyisappliedasscheduled.However,
this approach is not practical and severe hepatic toxicity
caused by HCV reactivation should be avoided. In order
to prevent HCV reactivation leading to hepatic toxicity,
methods to identify risk factors which can be easily used
at clinical sites are needed. Various questions remain to
be answered such as (1) whether concomitant ribavirin or
interferon should be used for current therapy, and if so,
(2) whether they should be used from the beginning of
treatment or at the end of existing treatment. There are no
reports on chemotherapy with concurrent use of rituximab.
Future clinical studies are needed to clarify these questions.
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